Secretariat Time Programme
12:00 - 13:30


Topouzis Stavros
Laboratory of Molecular Pharmacology,
work phone: 011-(30)-2610-962364 | 962365
Department of Pharmacy, Health Sciences School
e-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it  
University of Patras, Rio 26504 GREECE
Additional Appointments: Αdjunct Associate Professor of Pharmacology and Toxicology, Pennsylvania State University, USA (Oct 2009-)


1985: Pharmacy Degree, Aristotelian University of Thessaloniki, Greece
1986: Diplôme d’Etudes Approfondies (DEA) de Pharmacologie et Pharmacochimie, Universite Louis Pasteur, Strasbourg, France.
1989:Doctorat de Pharmacologie Moleculaire et Cellulaire, Universite Louis Pasteur, Strasbourg, France.

  • 1985-1990 Pharmacol. Moleculaire et Cellulaire , Faculte de Pharmacie U. Louis Pasteur and Merrel-Dow Research Institute Strasbourg, FRANCE , Doctoral student / Researcher Nitric Oxide, Endothelin Molecular Mechanisms of Arterial Contractility
  • 1990-1992 Dept. of Pharmacology/Toxicology Medical College of Georgia Augusta, Georgia USA, Research Fellow and Graduate School Lecturer Endothelial and Vascular Smooth Muscle cell (SMC) Biology
  • 1992-1998 Dept. of Pathology Baylor College of Medicine Houston, Texas, USA Research Associate (Junior Faculty) Vascular Wall Morphogenesis SMC Lineage Diversity
  • 1998-1999 Cell Biology MetaMorphix, Inc. Baltimore, Maryland USA Research Scientist Myostatin, Skeletal Muscle growth Glucose homeostasis
  • 1999-2006 Discovery Biology / Oncology ZymoGenetics Inc. Seattle, Washington, USA Senior Scientist / Project Leader Protein-based Therapeutics for Cancer, Vascular and Immune Diseases, and Regenerative Medicine
  • 2006- Lab. Of Molecular Pharmacology Dept. of Pharmacy Univeristy of Patras, Patras, GREECE Assistant Professor Biology of arterial smooth muscle and endothelial cells in Vascular and Inflammatory diseases
Current Financial Support
  1. Principal Investigator: K. Karatheodori Research Excellence Grant, “Modulation of the smooth muscle cell phenotype by alpha-1 adrenergic receptors”, (30K Euros, U of Patras, 2009-12)
  2. Co-Investigator, Synergasia Consortium Grant (Academia-Industry cooperation) “Discovery of Plant-Derived Angiogenesis-Modulating Molecules” (Total Budget: 1.9Million Euros, of which 380K budgeted to the Lab. of Mol. Pharmacology, U of Patras, Coordinator: Lab. of Pharmacognosy, U of Athens, 2011-14)
  3. National Representative and MC Member, FP7 COST EU-Consortium grant “ENOG – European Network on Gasotransmitters: from basic science to therapeutic application”, (Coordinator: Lab of Mol. Pharmacology, U of Patras, 2011-15)
  4. Co-Investigator and Work Package Leader, REGPOT EU Project (started 01/2011) “ESTABLISHMENT OF A CENTRE OF EXCELLENCE FOR STRUCTURE-BASED DRUG TARGET CHARACTERIZATION: STRENGTHENING THE RESEARCH CAPACITY OF SOUTH-EASTERN EUROPE” (“SEE-DRUG”), Total Budget: 3.2Million Euros, of which ~2.9 Millions to the Dept. of Pharmacy (Coordinator: Lab. of Structural Biology, Dept. of Pharmacy, U of Patras, 2011-15)
  5. Co-Investigator and Work Package Leader, THALIS Consortium “Hydrogen sulfide, a new endogenous regulator of angiogenesis: signaling, physiology/pathophysiology and development of pharmacological inhibitors” (Total budget: 500KEuros, Coordinator: Lab. of Mol. Pharmacology, Dept. of Pharmacy, U of Patras, 2011-15)


  • Z Zhou, M von Wantoch Rekowski, C Coletta, C Szabo, M Bucci, G Cirino, S Topouzis, A Papapetropoulos and A Giannis (2012)
    Thioglycine and L-thiovaline: Biologically active H2S-donors, Bioorg. Med. Chem., 20(8):2675-8
  • JA Thomas, RA Deaton, NE Hastings, Y Shang, CW Moehle, U Eriksson, S Topouzis, BR Whamhoff, BR Blackman and GK Owens (2009)
    Platelet-Derived Growth Factor PDGF-DD, a novel mediator of smooth muscle cell phenotypic modulation, is upregulated in endothelial cells exposed to atherosclerotic-prone flow patterns, Am. J. Physiol. Heart Circ. Physiol.,296(2):H442-52
  • SR Dillon, C Sprecher, A Hammond, J Bilsborough, M Rosenfeld-Franklin, SR Presnell, HS Haugen, M Maurer, B Harder, J Johnston, S Bort, S Mudri, JL Kuijper, T Bukowski, P Shea, D Dong, M Dasovich, FJ Grant, L Lockwood, SD Levin, C LeCiel, K Waggie, H Day, S Topouzis, J Kramer, R Kuestner, D Foster, J Parrish-Novak and JA Gross (2004)
    Interleukin 31, a cytokine produced by T cells, induces dermatitis in mice Nature Immunol., 5, 752-760
  • W Xu, SR Presnell, J Parrish-Novak, W Kindsvogel, S Jaspers, Z Chen, SR Dillon, Z Gao, T Gilbert, K Madden, S Schultzmeyer, L Yao, TE Whitmore, Y Chandrasekher, FJ Grant, M Maurer, L Jelinek, H Storey, T Brender, A Hammond, S Topouzis, CH Clegg and DC Foster (2001)
    A soluble class II cytokine receptor, IL-22RA2, is a naturally occurring IL-22 antagonist. Proc. Natl. Acad. Sci. USA, 98, 9511-9116
Inventor in>13 Published Patent Applications

Issued us Patents
  • United States Patent 7,172,757 February 6, 2007 Method of treating fibroproliferative disorders Inventors: Hart; Charles E. (Woodinville, WA); Topouzis; Stavros (Seattle, WA), Gilbertson; Debra G. (Seattle, WA) Assignee: ZymoGenetics, Inc. (Seattle, WA)
  • United States Patent 7,045,498 May 16, 2006 Soluble Zcytor11 cytokine receptors Inventors: Kindsvogel; Wayne R. (Seattle, WA); Topouzis; Stavros (Seattle, WA) Assignee: ZymoGenetics, Inc. (Seattle, WA)
  • United States Patent 6,827,938 December 7, 2004 Compositions and methods for improving kidney function Inventors: Hart; Charles E. (Woodinville, WA); Topouzis; Stavros (Seattle, WA) Assignee: ZymoGenetics, Inc. (Seattle, WA)
  • United States Patent 6,630,142 October 7, 2003 Method of treating fibroproliferative disorders Inventors: Hart; Charles E. (Woodinville, WA); Topouzis; Stavros (Seattle, WA), Gilbertson; Debra G. (Seattle, WA) Assignee: ZymoGenetics, Inc. (Seattle, WA)
  • United States Patent 6,368,597 April 9, 2002 Methods of treating diabetes Inventors: Strassmann; Gideon (Washington, DC), Liang; Li-fang (Elkridge, MD); Topouzis; Stavros (Elkridge, MD Assignee: MetaMorphix, Inc. (Baltimore, MD)

Research Focus
My work has in major part focused on the pathophysiology and pharmacology of blood vessel wall. More specifically, I have been studying the role(s) of the constituent endothelial and smooth muscle cells in determining blood pressure and vascular resistance, regulating inflammatory and thrombotic processes, participating in solid tumor and in wound angiogenesis, or contributing to chronic cardiovascular diseases (e.g. atherosclerosis, thrombosis, arterial calcification, restenosis).

At the cellular and molecular levels, my research has addressed several aspects of the biology and differentiation control of vascular smooth muscle and endothelial cells, triggered by morphogenetic cues (TGF-β and PDGF) and transcriptional regulators (SRF, Myocardin), the genetic regulation of disease development (Myocardin polymorphisms) and the interactions of the blood vessel wall with circulating cells such as monocytes/macrophages, platelets and T-cells (IL-22RA2, TFPI-2).

The current research efforts of my University of Patras group address the following:

a) Regulation of the phenotypic plasticity and function in vascular smooth muscle cells and endothelial cells by key endogenous systems / potential therapeutic targets. The latter include the adrenergic receptor and the PDGF / PDGF-R systems. More recently, we have embarked on the elucidation of the physiological and pharmacological role of the gasotransmitter hydrogen sulfide (H2S) and the FSH / FSH-R systems in the vasculature.

b) Characterization of the mechanisms by which secreted factors, such as TGF-β and PDGF, can influence the process of endothelial-to-mesenchymal transition (EndMT), with emphasis on the role of the transcriptional regulators SRF and Myocardin. EndMT is critical in angiogenesis and in tissue remodeling (e.g. heart hypertrophy), regulates endothelial phenotypic/functional characteristics in health and disease and responds to physiological stimuli such as hypoxia and mechanical stress.